MedTrace Logo

A Clinical Study of Semaglutide Nasal Spray in Overweight or Obese Adults

NCT07465965 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-03-12

No results posted yet for this study

Summary

The specific aim of this study is to examine the Safety, Tolerability and Pharmacokinetic of Semaglutide Nasal Spray compared with placebo and positive control in Adult Overweight or Obese Participants.

Conditions

Interventions

DRUG

Semaglutide Nasal Spray

WL1006

DRUG

Placebo

WL1006

DRUG

Semaglutide Injection

Wegovy®

Sponsors & Collaborators

  • Shanghai World Leader Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-02
Primary Completion
2026-08-21
Completion
2026-08-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07465965 on ClinicalTrials.gov